The Pharma Data

JANUARY 4, 2021

Centers for Disease Control and Prevention has said that Covid-19 vaccines “are not interchangeable,” and that “the safety and efficacy of a mixed-product series have not been evaluated. . ” Both vaccines teach immune cells to recognize and fight off the virus. © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Virus Hospitals Production 52

The Pharma Data

FEBRUARY 1, 2021

They spent about an hour at the Huanan Seafood Market, which was the site of an outbreak of the virus in December 2019, the Associated Press reported. Initially, experts suspected the new coronavirus came from wild animals sold at the market, but the site has been largely ruled out as a source of the virus. © 2021 HealthDay.

Vaccine 52

Vaccine Virus Marketing Compliance 52

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus.

RNA 97

RNA Virus DNA Vaccine 97

The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. The research team, including scientists from the U.S.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

The Pharma Data

SEPTEMBER 30, 2021

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a replacement treatment that would keep metastatic cancers cornered from the lungs. It involves a bodily injection of a virus called the cowpea mosaic virus. The research was published Sept.

Virus 52

Virus Engineering Treatment Research 52

The Pharma Data

JANUARY 27, 2021

27, 2021 — Heart disease remains the leading cause of death worldwide, with 18.6 million deaths attributed to cardiovascular disease (CVD) globally in 2019, according to a report from the American Heart Association published online Jan. © 2021 HealthDay. Posted: January 2021. WEDNESDAY, Jan. Virani, M.D.,

Disease 52

Disease Virus Pharmaceuticals 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. billion expected from signed advance purchase agreements for fiscal 2021, Bancel said in a Monday call with investors. 18, 2020 ). Martin Berman-Gorvine.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We Second Quarter 2021 Financial Results. Total second quarter 2021 revenue of $6.2 As of June 30, 2021, Gilead had $7.4

Science 52

Science Production Treatment FDA 52

The Pharma Data

JUNE 26, 2021

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. However, the discovery does show that the virus can change in unexpected ways and find new ways to cause infection. Now, researchers at Washington University School of Medicine in St. and Hubert C.

Virus 52

Virus Cell Biology Vaccine Research 52

The Pharma Data

APRIL 7, 2022

announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). NYSE: PFE) and ReViral Ltd.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company. population.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

JANUARY 11, 2021

Pfizer and BioNTech reported that their COVID-19 vaccine appears to be effective against a key mutation in new variants of the SARS-CoV-2 virus that causes COVID-19. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. A study published by the U.S. Other Industry News. and now 501.V2,

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

SEPTEMBER 30, 2021

We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”. In the U.S., About MenQuadfi In the U.S.,

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

MARCH 3, 2022

Today’s decision is a pivotal next step in our path towards potential regulatory approval for our maternal RSV vaccine candidate and is an important milestone in our efforts to help address the detrimental impact RSV disease has on infants,” said Kathrin U. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

JULY 23, 2021

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print , demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta/Gamma variants of the SARS-CoV-2 virus.

Disease 52

Disease Vaccine Virus Trials 52

The Pharma Data

MARCH 22, 2022

Consistent results were observed at 200 days of follow-up with respect to CMV reactivation, clinically significant CMV infection, and CMV disease. Real-World Outcomes for Primary Prophylaxis of CMV Infection and Disease Using PREVYMIS. See additional results below.

Disease 52

Disease Virus DNA Therapies 52

The Pharma Data

DECEMBER 21, 2020

Kaiser Permanente has announced that it will extend its waiver for most member out-of-pocket costs for inpatient and outpatient services related to the treatment of COVID-19 through at least March 31, 2021 , or as long as the ongoing public health emergency lasts. OAKLAND, Calif. ,

Virus 52

Virus Clinical Research Treatment Disease 52

Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections.

Hospitals 137

Hospitals Virus Medical Schools Science 137

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Adeno-associated virus vector as a platform for gene therapy delivery.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses within the tract and therefore the lung. Breathe in, exhale. doi: 10.1016/j.isci.2021.103037.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

AUGUST 3, 2021

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. More than 60 million patients worldwide suffer from this disease, approx.

Research 52

Research Treatment Clinical Trials Production 52

The Pharma Data

JANUARY 21, 2021

21, 2021 — U.S. President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. © 2021 HealthDay. Posted: January 2021. THURSDAY, Jan. Source link.

Vaccine 52

Vaccine Virus RNA Research 52

The Pharma Data

DECEMBER 2, 2020

MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. The company’s current pipeline features programs in infectious diseases and immuno-oncology.

Disease 52

Disease Virus Treatment Therapies 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 128

Therapies Virus DNA Clinical Trials 128

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Let’s take a deeper dive into these challenges.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

The Pharma Data

JANUARY 16, 2021

17, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians, public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Hospitals 52

Hospitals Vaccine Laboratories Disease 52

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 97

DNA Laboratories Hospitals Virus 97

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index.

Vaccine 52

Vaccine Production FDA Disease 52

New Drug Approvals

DECEMBER 26, 2022

1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03 Immunoglobulin g1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal med18897.gamma.1-chain), 2] [3] Nirsevimab is designed to bind to the fusion protein on the surface of the RSV virus. [4]

Virus 52

Virus Clinical Trials Trials Disease 52

Drug Target Review

JANUARY 15, 2024

Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells. The FEBS Journal 288:6159–6173 (2021).

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

DECEMBER 18, 2020

These agreements mean that all COVAX’s 190 participating and eligible economies will be able to access doses to protect vulnerable groups in the first half of 2021. billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC. First deliveries in Q1 2021.

Vaccine 52

Vaccine Government International Virus 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JANUARY 13, 2021

President and CEO of Verona Pharma, said: “Completing enrollment of the pilot study in COVID-19 is an important milestone and we are on track to report top-line results in the second quarter of 2021. LONDON and RALEIGH, N.C., patients hospitalized with COVID-19. For more information, please visit www.veronapharma.com.

Hospitals 52

Hospitals Clinical Trials Therapies Treatment 52

The Pharma Data

JANUARY 26, 2021

26, 2021 — The first known U.S. “We know that even as we work hard to defeat COVID-19, the virus continues to evolve as all viruses do,” Minnesota Health Commissioner Jan Malcolm said in a statement. Centers for Disease Control and Prevention. © 2021 HealthDay. Posted: January 2021. Professional.

Virus 52

Virus Disease Research 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — The bacteria in your gut may play a role in the severity of COVID-19 infection and the strength of your immune system response, a new study suggests. “Restoration of the missing beneficial bacteria might boost our immunity against SARS-CoV2 virus and hasten recovery from the disease,” she said.

Virus 52

Virus Hospitals Disease Research 52